Experiments were carried out to investigate the possibility of providing chemical protection to blood forming organs and increasing animal survival rates in lethally irradiated H mice and Wistar rats. A 300 mg/kg dose of the radioprotective agent was injected intraperitoneally 15-30 min prior to irradiation with 8.0 Gy gamma rays. Recorded were 30-day survival rates and the state of hemopoiesis on days 3 and 10 postradiation as judged by spleen weight and total counts of spleno- and myelokaryocytes. At 8.0 Gy exposure was observed to cause severe spleen and bone-marrow hypoplasia on day 3 postradiation. Adeturone pretreatment provided slight protection to rat spleen and mouse bone marrow; by day 10, however, both animal species exhibited a vigorous proliferative response of nucleated cells in the bone marrow, which resulted in 75% survival rate among animals exposed to a lethal radiation dose.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
gene therapy induces effective antitumor immunity in mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.
Elife
February 2025
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Houston, United States.
Expression of , a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of induces DNA damage, apoptosis, and cell-cycle arrest. We investigated antitumor immune responses in aPD1/ NSCLC in humanized-mice.
View Article and Find Full Text PDFMetabolomic changes in preterminal serum samples of rhesus macaques exposed to two different lethal doses of total-body gamma-radiation.
Sci Rep
October 2024
Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA.
Article Synopsis
- Exposure to ionizing radiation causes cellular and molecular damage, leading to tissue and organ injury, which we examined in rhesus macaques exposed to lethal doses of radiation (7.2 Gy and 7.6 Gy).
- We analyzed blood samples collected before and after exposure using advanced mass spectrometry techniques, focusing on identifying metabolic changes related to radiation exposure, especially in preterminal samples (just before death).
- Our findings revealed significant metabolic disruptions, particularly in sphingolipid metabolism, which could serve as potential biomarkers for predicting lethality in radiation exposure situations, aiding in disaster response planning.
Disruptions in the bone remodeling cycle that occur with increasing age lead to degeneration of the skeleton and increased risk of fragility fractures. Our understanding of how bone remodeling within cortical bone is controlled and altered with age in males and females is limited. Here, we generated bone marrow chimeric mice to understand the impacts of age and sex on bone remodeling.
View Article and Find Full Text PDFEffect of Age at Time of Irradiation, Sex, Genetic Diversity, and Granulopoietic Cytokine Radiomitigation on Lifespan and Lymphoma Development in Murine H-ARS Survivors.
Radiat Res
September 2024
Department of Medicine, Divisions of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46202.
Acute, high-dose radiation exposure results in life-threatening acute radiation syndrome (ARS) and debilitating delayed effects of acute radiation exposure (DEARE). The DEARE are a set of chronic multi-organ illnesses that can result in early death due to malignancy and other diseases. Animal models have proven essential in understanding the natural history of ARS and DEARE and licensure of medical countermeasures (MCM) according to the FDA Animal Rule.
View Article and Find Full Text PDFA phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma.
Leuk Lymphoma
December 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Several vaccine strategies have been tested for the treatment of follicular lymphoma; however, none have proven successful. In a phase I dose-escalation protocol, we developed a vaccine consisting of lethally irradiated whole lymphoma cells admixed with K562 cells that constitutively secreted granulocyte-macrophage colony-stimulating factor (GM-K562)(ClinicalTrials.gov identifier: NCT00487305).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!